Literature DB >> 18270493

Complement split products C3a and C4a are early markers of acute lyme disease in tick bite patients in the United States.

Ritchie C Shoemaker1, Patricia C Giclas, Chris Crowder, Dennis House, M Michael Glovsky.   

Abstract

BACKGROUND: Current laboratory markers do not readily detect acute Lyme disease. We assessed the utility of complement and its split products as markers of Lyme disease in patients shortly after a tick bite.
METHODS: Thirty-one consecutive acute Lyme disease patients, 14 with and 17 without erythema migrans (EM) skin rash, seen by a physician within 96 h of a tick bite were matched with 24 consecutive tick bite patients without Lyme disease symptoms and 46 healthy control subjects. Complement and split products measured included factor B, Bb, C4, C3c, C3a(des Arg), C4a(des Arg), C1q- and C3d-containing immune complexes, and C2.
RESULTS: C2, C4, C3 and factor B levels were within normal ranges in all groups. C3a and C4a levels were significantly higher in acute Lyme disease patients than in tick bite and healthy control groups (both p < 0.001). All acute Lyme disease patients, regardless of EM, had elevated levels of C3a or C4a. Few tick bite controls had elevated levels of C3a (2/20) or C4a (5/24) and only 1 of the healthy control subjects had elevated C3a (0/46) or C4a (1/32).
CONCLUSIONS: These findings suggest that C3a and C4a may be useful markers of Lyme disease in patients seen shortly after tick bite, even in those without EM. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270493     DOI: 10.1159/000116362

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  4 in total

1.  Chronic fatigue syndrome and complement activation.

Authors:  Robert Dennis Geller; Patricia C Giclas
Journal:  BMJ Case Rep       Date:  2009-03-17

2.  Lyme disease: the next decade.

Authors:  Raphael B Stricker; Lorraine Johnson
Journal:  Infect Drug Resist       Date:  2011-01-07       Impact factor: 4.003

3.  Transcriptomic signatures in whole blood of patients who acquire a chronic inflammatory response syndrome (CIRS) following an exposure to the marine toxin ciguatoxin.

Authors:  James C Ryan; Qingzhong Wu; Ritchie C Shoemaker
Journal:  BMC Med Genomics       Date:  2015-04-02       Impact factor: 3.063

Review 4.  The Potential of Omics Technologies in Lyme Disease Biomarker Discovery and Early Detection.

Authors:  Alaa Badawi
Journal:  Infect Dis Ther       Date:  2016-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.